T. Rowe Price Associates
OGEN icon

T. Rowe Price Associates’s Oragenics OGEN Stock Holding History

T. Rowe Price Associates’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-44
Closed -$36K – 3009
2021
Q4 		$36K Hold
44
– – ﹤0.01% 2943
2021
Q3 		$51K Buy
+44
New +$53.1K ﹤0.01% 2902

Other funds holding OGEN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SBF
Sara-Bay Financial Sarasota, Florida $375M AUM 56.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates's OGEN Position: Q1 2022 in Review

T. Rowe Price Associates sold out of Oragenics (OGEN) in Q1 2022, closing a stake of 44 shares — an estimated $36K sold.

T. Rowe Price Associates first reported a position in OGEN in Q3 2021 and held it in 2 quarters. The position peaked at $51K in Q3 2021. 24 funds tracked by Wall St. Rank hold OGEN as of Q1 2022.

  • T. Rowe Price Associates reported no remaining Oragenics position as of Q1 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 44 Oragenics shares in Q1 2022, an estimated $36K.
  • T. Rowe Price Associates first reported a position in Oragenics in Q3 2021 and held it in 2 quarters.
  • T. Rowe Price Associates's Oragenics position peaked at $51K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Oragenics as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.